Redifferentiation Therapy in Thyroid Cancer

Park, Jin-Woo

doi:10.16956/kjes.2002.2.2.83

Search citation statements

Order By: Relevance

Paper Sections

Select...

Markers and Signal Pathways1

Markers1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the dedifferentiation process, the thyroid carcinoma loses thyroid-specific gene expression, contributing to the lack of response to radioiodine ablation therapy in ATC [14].…”

Section: Markers and Signal Pathwaysmentioning

confidence: 99%

See 1 more Smart Citation

Novel Approaches in Anaplastic Thyroid Cancer Therapy

Hsu¹,

Yu²,

Audhya³

et al. 2014

The Oncologist

View full text Add to dashboard Cite

Anaplastic thyroid cancer (ATC), accounting for less than 2% of all thyroid cancer, is responsible for the majority of death from all thyroid malignancies and has a median survival of 6 months. The resistance of ATC to conventional thyroid cancer therapies, including radioiodine and thyroid‐stimulating hormone suppression, contributes to the very poor prognosis of this malignancy. This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways. Lastly, novel approaches and agents involving the Notch1 pathway, nuclear factor κB, Trk‐fused gene, cancer stem‐like cells, mitochondrial mutation, and tumor immune microenvironment are discussed. With a better understanding of the biological process and treatment modality, the hope is to improve ATC outcome in the future.

show abstract

“…During the dedifferentiation process, the thyroid carcinoma loses thyroid-specific gene expression, contributing to the lack of response to radioiodine ablation therapy in ATC [14].…”

Section: Markers and Signal Pathwaysmentioning

confidence: 99%

“…Interestingly, ATC can develop from 1% of patients with DTC [14]. Normal thyrocytes initially undergo early mutations of ret, ras, BRAF, or a paired box homeotic gene 8 (PAX8)-peroxisome proliferator activated receptor g (PPARg) to transform into DTCs [21][22][23][24].…”

Section: Markersmentioning

confidence: 99%